Articles tagged "Antilymphocyte antibodies"

2020 American Transplant Congress
Causal Relationship between Anti-Thymocyte Globulin Induction Therapy and Development of Monomorphic PTLD in Renal Transplant Recipients
K. Soliman¹, H. Ali², T. Fulop¹, A. Osman³, A. Halawa⁴
¹Medicine, Medical University of South Carolina, Charleston, SC, ²Medicine, Royal Stoke, Royal Stoke, United Kingdom, ³Medicine, Cairo University, Cairo, Egypt, ⁴Medicine, University of Liverpool, Liverpool, United Kingdom
*Purpose: The aim of our study is to explore the causality between ATG and different types of post-transplant lymphoproliferative disorder (PTLD) in renal transplant recipients…
2020 American Transplant Congress
Comparison of Short-Term Outcomes of Induction Therapy with Alemtuzumab versus Rabbit Antithymocyte Globulin in Lung Transplantation
V. Liu, M. W. Soto-Arenall, A. Patel
Pharmacy, Mayo Clinic, Jacksonville, FL
*Purpose: To identify the short-term efficacy and safety outcomes of alemtuzumab (C1H) versus rabbit antithymocyte globulin (rATG) in lung transplant patients. The objectives are to…
2020 American Transplant Congress
A Recombinant, Fully Human ATG Polyclonal Antibody Drug Drives Immune Cell Depletion in a Model of Graft-versus-Host Disease
S. M. Keating, A. S. Adler, R. A. Mizrahi, J. Leong, M. A. Asensio, Y. W. Lim, A. R. Niedecken, Y. Chiang, R. Leong, D. S. Johnson
Immunology, GigaGen, South San Francisco, CA
*Purpose: Anti-thymocyte globulin (ATGs) are polyclonal antibody products that target and deplete T cells for immunosuppression in transplantation (prophylaxis of rejection). Since ATGs are derived…
2020 American Transplant Congress
Depletional Profiles of Human and Rhesus Specific Anti-Thymocyte Globulins in Rhesus Macaques
B. I. Shaw¹, R. Schmitz¹, D. M. Magnani², F. Leopardi¹, A. D. Kirk¹
¹Surgery, Duke University, Durham, NC, ²Medicine, MassBiologics of the University of Massachusetts Medical School, Boston, MA
*Purpose: Rabbit anti-human ATG (rATG; Thymoglobulin®) is the most commonly used formulation for depletional induction therapy in the United States. However, given that it is…
2020 American Transplant Congress
Outcomes of Acute Allograft Rejection Treatment with R Anti-Thymocyte Globulin (r-ATG) One Year Post Kidney Transplant
M. Yaqub, A. Riaz, D. Mishler, O. Adebiyi, T. Taber, A. Sharfuddin
Indiana University School of Medicine, Indianapolis, IN
*Purpose: Acute allograft rejection is considered one of the major causes of renal allograft dysfunction. Despite maximal anti-rejection therapy grafts may not regain baseline function.…
2020 American Transplant Congress
Anti-Thymocyte Globulins Induced Immunomodulatory Effect and Increased Regulatory T Cell in a In Vitro Model of Allogeneic Cell Coculture
M. Colladant¹, J. Lion², P. Saas³, S. Perruche³, D. Ducloux¹, N. Mooney², J. Bamoulid¹
¹Nephrologie, Dialyse et Transplantation, CHU de Besançon, Besancon, France, ²Equipe INSERM: Endothelium, Inflammation et Alloreactivity INSERM UMR-S 976, Paris, France, ³INSERM U1098 RIGHT, Université de Franche-Comté EFS Bourgogne Franche-Comté, Besancon, France
*Purpose: Two types of Anti-Thymocyte Globulins (ATG) are commonly used in renal transplantation (Thymoglobuline and Grafalon) and induce severe, dose-dependent and sometimes persistent CD4+ T…
2020 American Transplant Congress
Carfilzomib-Based Desensitization: Effects on HLA, Non-HLA, Auto, and Antiviral Antibodies
S. Tremblay¹, E. Portwood¹, A. R. Shields², R. R. Alloway¹, P. A. Brailey¹, E. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²U Cincinnati, Christ Hospital, Cincinnati, OH
*Purpose: An important question in plasma cell (PC) therapies is the specificity of therapy for PC populations. It is known that plasmablast populations are exquisitely…
2020 American Transplant Congress
Thymoglobulin Dose and Incidence of Biopsy Proven Acute Rejections in the Early Post Transplant Period
K. Shimko, K. Schonder, D. Jorgensen, K. Kalra, A. Cherukuri, R. Mehta, I. Melgarejo, P. Sood, S. Hariharan, R. Mehta
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Optimal dosing of thymoglobulin (ATG) for induction has not been well defined. Our protocol aims for 5-6mg/kg cumulative dose divided over 4 doses. However,…
2020 American Transplant Congress
Short Term Outcomes in Kidney Transplant Patients Receiving De Novo Belatacept with Anti-Thymocyte Globulin Induction
B. Carlson, P. Cabrera, T. Harrison, K. Tejani, A. Centeno
Pharmacy, Jackson Memorial Hospital, Miami, FL
*Purpose: Mainstay immunosuppressive therapy after kidney transplant is a calcineurin inhibitor (CNI) based regimen. Nephrotoxicity is a common adverse effect of CNIs which can lead…
2019 American Transplant Congress
Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model
J. Lei¹, H. Deng¹, K. Lee¹, C. Peters¹, G. Rickert¹, R. Ivy¹, M. Coronel², E. Yolcu³, H. Shirwan⁴, A. García⁵, J. Markmann¹
¹Surgery, Massachusetts General Hospital, Boston, MA, ²Surgery, Georgia Institute of Technology, Atlanta, GA, ³Institute for Cellular Therapeutics, University of Louisville School of Medicine, louisville, KY, ⁴Department of Microbiology and Immunology, University of Louisville School of Medicine, louisville, KY, ⁵School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA
*Purpose: In the current standard clinical transplant approach, islet cells are administered intravenously into the portal system where they lodge in the liver. This approach…